Candel Therapeutics' cancer drug meets late-stage trial goals

Candel Therapeutics

11/12/2024 12:08

Dec 11 (Reuters) - Candel Therapeutics  CADL.O  said on
Wednesday its experimental prostate cancer drug met the main
goal of a late-stage trial, sending the company's shares up 64%
in premarket trading.

 (Reporting by Kamal Choudhury in Bengaluru Editing by Sriraj
Kalluvila)
 ((Kamal.Choudhury@thomsonreuters.com;))